Aurobindo Pharma Ltd. has evolved into a knowledge driven, R&D focused company, with its manufacturing and marketing infrastructure spread across many countries. It is fast becoming a conglomerate in the world of Pharmaceutical Generics.

Aurobindo has invested significant resources for the regulated markets by designing five of its units for APIs and five units for Finished Dosages which are approved by US FDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil, and TGI- Australia. Among the largest vertically integrated pharmaceutical companies in India, Aurobindo has a robust product portfolio of over 400 generic specialties.